<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bankhead, Charles</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Jones, Paul W.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">TESRA Study Results</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-10</style></pages><abstract><style  face="normal" font="default" size="100%">Results from the Treatment of Emphysema with a Selective Retinoid Agonist [TESRA; NCT00413205] study showed that emphysema patients had a mixed response to treatment with the retinoid agonist palovarotene. Treatment with palovarotene failed to meet the primary endpoint of improving lung function (FEV1) in the overall analysis.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>